Tel. +44 (0)20 8722 4122

Fax. +44 (0)20 8722 4359

Email. tgl@icr.ac.uk

Laboratory Address:

TGLclinical

Institute of Cancer Research

15 Cotswold Road

Sutton SM2 5NG

UNITED KINGDOM

TGLclinical ICR_F_Col

The Institute of Cancer Research: Royal Cancer Hospital

Company Limited by Guarantee. Registered in England No. 534147.

A Charity, Not for Profit, VAT Registration No. GB 849 0581 02

ICR Registered Address:

123 Old Brompton Road; London; SW7 3RP

Logo_for website

Cancer Predisposition Gene discovery at ICR  include:

 

- Breast / ovarian cancer genes BRCA2, CHEK2, PALB2, BRIP1 and RAD51D

 

- Childhood syndromic genes such as PALB2, BUB1B, EZH2,DNMT3A,  CEP57, REST, CTR9 and PP2A

 

The ICR has also been highly successful in using GWAS to identify common cancer-associated variants for breast, colorectal, lung, prostate, testicular cancer, glioma and Wilms tumor.

 

In partnership with Illumina, the unit has developed a next-generation sequencing assay to analyse the 94 cancer prediposition genes and 284 cancer GWAS variants known as the TruSight cancer panel.

 

Through a Wellcome Trust funded initiative known as the Mainstreaming Cancer Genetics programme the unit developed the  TruSight cancer panel which has now been optimised, validated and implemented for use in TGLclinical.

Key publications

Realizing the promise of cancer predisposition genes. Nature 2014 505:308-308

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013 17;493(7432):406-10

Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height. Oncotarget. 2011 2(12):1127-33

Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 2011 7;43(9):879-82

Mutations in CEP57 cause mosaic variegated aneuploidy syndrome. Nature Genetics 2011 43(6):527-9

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nature Genetics 2007 39(2):165-7

Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics 2006 38(11):1239-41

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics 2002 31(1):55-9

Identification of the breast cancer susceptibility gene BRCA2. Nature 1995 378(6559):789-92

ICR Research